Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Res. 2017 Feb 27;15(7):905–914. doi: 10.1158/1541-7786.MCR-16-0369

Figure 1. KRAS is associated with USP18 expression in murine lung cancer cells.

Figure 1

(A) Engineered stable gain of USP18 expression increased lung cancer cell growth and (B) Constitutive loss of USP18 expression by shRNAs decreased cell growth in 393P and LKR13 murine lung cancer cell lines. Proliferation was monitored over 4 days. Growth of these cell lines was normalized to their respective proliferation on day 1. Representative immunoblots confirmed engineered expression and knockdown respectively of USP18 protein in Figure 2A and B. (C) There is no association between Kras and Usp18 mRNA levels in murine lung cancer cell lines. Expression of Kras and Usp18 mRNAs were analyzed by qRT-PCR assays. Kras and Usp18 mRNA expression profiles were quantified relative to respective Gapdh mRNA and normalized to expression in C10 murine lung epithelial cells. (D) There is an association between KRAS and USP18 protein levels in murine lung cancer cell lines. Basal KRAS and USP18 protein expression profiles were quantified relative to respective actin expression and normalized to levels in C10 cells. The representative USP18 immunoblot was exposed for a brief time to avoid overexposure in lanes with abundant USP18 expression.